A Phase 2 Open-Label, Randomized, Multi-Center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer.

Trial Profile

A Phase 2 Open-Label, Randomized, Multi-Center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Leuprorelin; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
    • 05 May 2013 Primary endpoint 'Testosterone-levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top